Tesaro Inc. (TSRO) PT Raised to $120.00
Tesaro Inc. (NASDAQ:TSRO) had its target price hoisted by investment analysts at Robert W. Baird to $120.00 in a research report issued to clients and investors on Monday. Robert W. Baird’s price objective would indicate a potential upside of 20.89% from the company’s current price.
TSRO has been the subject of a number of other reports. RBC Capital Markets restated an “outperform” rating and issued a $122.00 price objective on shares of Tesaro in a report on Wednesday, August 24th. Leerink Swann boosted their target price on shares of Tesaro from $65.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, June 30th. Wedbush reiterated a “buy” rating on shares of Tesaro in a research note on Friday, August 5th. Citigroup Inc. boosted their target price on shares of Tesaro from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, August 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Tesaro from $122.00 to $128.00 and gave the company an “outperform” rating in a research note on Monday. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $102.69.
Tesaro (NASDAQ:TSRO) opened at 99.26 on Monday. The stock has a 50 day moving average price of $96.42 and a 200-day moving average price of $68.96. The company’s market capitalization is $5.10 billion. Tesaro has a 12-month low of $29.51 and a 12-month high of $110.48.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/tesaro-inc-tsro-pt-raised-to-120-00.html
Tesaro (NASDAQ:TSRO) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The company earned $36.60 million during the quarter, compared to analyst estimates of $4.98 million. During the same period in the previous year, the business earned ($1.51) EPS. Equities analysts predict that Tesaro will post ($7.36) EPS for the current fiscal year.
In related news, VP Jeffrey H. Hanke sold 29,166 shares of the company’s stock in a transaction on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total value of $2,509,442.64. Following the completion of the transaction, the vice president now owns 29,166 shares of the company’s stock, valued at approximately $2,509,442.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Edward C. English sold 7,000 shares of the company’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $88.54, for a total transaction of $619,780.00. Following the completion of the transaction, the vice president now directly owns 3,500 shares of the company’s stock, valued at approximately $309,890. The disclosure for this sale can be found here. 40.50% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 834 shares during the period. BlackRock Group LTD increased its position in Tesaro by 7.9% in the first quarter. BlackRock Group LTD now owns 162,499 shares of the biopharmaceutical company’s stock valued at $7,154,000 after buying an additional 11,880 shares during the period. BlackRock Fund Advisors boosted its stake in shares of Tesaro by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,293,906 shares of the biopharmaceutical company’s stock valued at $56,971,000 after buying an additional 23,384 shares in the last quarter. State Street Corp boosted its stake in shares of Tesaro by 0.7% in the first quarter. State Street Corp now owns 893,749 shares of the biopharmaceutical company’s stock valued at $39,349,000 after buying an additional 6,026 shares in the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Tesaro by 35.8% in the first quarter. Pictet Asset Management Ltd. now owns 55,000 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 14,500 shares in the last quarter. 88.81% of the stock is owned by institutional investors and hedge funds.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.